MG
MGROF.US Mustgrow Biologics Corp
- Market cap
- USD 17.6M
- P/E
- -
- P/B
- 4.97x
- ROE
- -41.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MGROF.US undervalued?
Graham numberThe Graham number of Mustgrow Biologics Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mustgrow Biologics Corp fundamental analysis
No fundamental analysis for Mustgrow Biologics Corp yet.
Mustgrow Biologics Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mustgrow Biologics Corp
MustGrow Biologics Corp., an agricultural biotechnology company, focuses on development and commercialization of natural biological technologies and products from mustard plants. The company provides Biocontrol technology platform to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and others; treat unwanted plant growth for use in organic agriculture, and home and garden markets, as well as agriculture markets where glyphosate has been ban…
Full company profileMustgrow Biologics Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mustgrow Biologics Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 12.9K | 6.48K | 4.71M | 398K | 8.29M | 3.07M |
| Gross Profit | 0.00 | 0.00 | 0.00 | - | - | - | - | 4.71M | 301K | 1.17M | 2.62M |
| Operating Income | -20.4K | -36.5K | -1.85M | -1.47M | -3.37M | -3.01M | -5.69M | -805K | -5.11M | -6.25M | -854K |
| EBITDA | - | - | - | - | -3.26M | - | -5.56M | -805K | -4.89M | -6.89M | -847K |
| Net Income | -20.4K | -36.5K | -1.89M | -1.52M | -3.31M | -3.06M | -5.57M | -677K | -4.89M | -7.26M | -2.08M |
| EPS | - | 0.00 | -0.08 | -0.04 | -0.08 | -0.07 | -0.11 | -0.01 | -0.09 | -0.12 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 937.00 | 192K | 534K | 4.09M | 3.37M | 9.70M | 7.13M | 6.94M | 5.42M | 3.09M | 7.16M |
| Total Liabilities | 30.1K | 59.8K | 1.02M | 1.06M | 1.05M | 1.25M | 1.90M | 1.35M | 3.25M | 2.23M | 2.11M |
| Shareholders' Equity | -29.2K | 132K | -486K | 3.03M | 2.32M | 8.46M | 5.24M | 5.58M | 2.17M | 867K | 5.05M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 4.03M | 3.31M | 9.62M | 7.02M | 6.82M | 3.00M | 919K | 4.37M |
| Total Debt | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.57K | -220K | -968K | -1.35M | -2.58M | -2.41M | -3.26M | -295K | -3.58M | -5.06M | -3.33M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -6.74K | -968K | -1.35M | -2.58M | -2.41M | -3.26M | -295K | -3.58M | -5.06M | -3.33M |
| Ratios | |||||||||||
| ROE | - | -27.5% | - | -50.1% | -142.4% | -36.2% | -106.2% | -12.1% | -225.3% | -837.0% | -41.1% |
| ROA | -2,181.8% | -19.0% | -354.4% | -37.1% | -98.2% | -31.6% | -78.0% | -9.8% | -90.3% | -234.6% | -29.0% |
| Net Profit Margin | - | - | -94,668.9% | - | - | -23,808.2% | -85,905.9% | -14.4% | -1,228.3% | -87.6% | -67.6% |
| Debt to Equity | - | 0.00x | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mustgrow Biologics Corp dividends
Mustgrow Biologics Corp has not paid dividends in the last 9 fiscal years.
Who owns Mustgrow Biologics Corp
- Insiders 9.18%
- Institutions 0.00%
- Public & others 90.82%
- Shares outstanding 70.4M
- Free float 63.1M
Mustgrow Biologics Corp company profile
- Company name
- Mustgrow Biologics Corp
- Ticker
- MGROF.US
- ISIN
- CA62822A1030
- Exchange
- USA Stocks
- Sector
- Basic Materials
- Industry
- Chemicals
- Fiscal year end
- December
- Address
- 201 1st Avenue South, Saskatoon, SK, Canada, S7K 1J5
- Phone
- 306 668 2652
- Website
- mustgrow.ca
About Mustgrow Biologics Corp
MustGrow Biologics Corp., an agricultural biotechnology company, focuses on development and commercialization of natural biological technologies and products from mustard plants. The company provides Biocontrol technology platform to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and others; treat unwanted plant growth for use in organic agriculture, and home and garden markets, as well as agriculture markets where glyphosate has been banned; and suppress sprouting, and treat disease and pathogen for storage and food preservation markets. It also offers TerraMG, a mustard-derived soil biopesticide technology. In addition, the company is developing TerraSante, an organic soil amendment and biofertility technology. Further, it sells biostimulants, micronutrients, nitrogen stabilizers, and foliars. Additionally, the company offers biological and regenerative agriculture solutions to support sustainable farming. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
Mustgrow Biologics Corp management
4- Mr. Todd L. Lahti CA, CFACFO & Corporate Secretary · born 1966
- Mr. Corey J. Giasson B.Sc., MBACOO & Director · born 1978
- Mr. Colin BletskyChief Commercial Officer & Director
- Mr. Kevin R. HelashChief Executive Officer · born 1964